ARROWHEAD PHARMACEUTICALS IN's ticker is ARWR and the CUSIP is 04280A100. A total of 101 filers reported holding ARROWHEAD PHARMACEUTICALS IN in Q3 2016. The put-call ratio across all filers is 1.42 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $778 | -21.8% | 28,950 | +3.7% | 0.01% | -28.6% |
| Q2 2023 | $995 | +26.3% | 27,909 | -10.0% | 0.01% | +40.0% |
| Q1 2023 | $788 | -35.9% | 31,023 | +2.3% | 0.01% | -44.4% |
| Q4 2022 | $1,230 | -99.9% | 30,326 | -7.7% | 0.01% | +12.5% |
| Q3 2022 | $1,086,000 | +93.9% | 32,847 | +106.6% | 0.01% | +100.0% |
| Q2 2022 | $560,000 | -41.2% | 15,902 | -23.1% | 0.00% | -20.0% |
| Q1 2022 | $952,000 | -24.3% | 20,691 | +9.1% | 0.01% | -16.7% |
| Q4 2021 | $1,257,000 | +29.5% | 18,965 | +21.9% | 0.01% | +20.0% |
| Q3 2021 | $971,000 | -8.5% | 15,559 | +21.5% | 0.01% | -16.7% |
| Q2 2021 | $1,061,000 | +46.7% | 12,807 | +17.5% | 0.01% | +50.0% |
| Q1 2021 | $723,000 | +5.7% | 10,896 | +22.2% | 0.00% | 0.0% |
| Q4 2020 | $684,000 | +183.8% | 8,914 | +59.4% | 0.00% | +100.0% |
| Q3 2020 | $241,000 | +11.6% | 5,593 | -64.7% | 0.00% | +100.0% |
| Q2 2018 | $216,000 | +390.9% | 15,849 | +93.1% | 0.00% | – |
| Q2 2016 | $44,000 | – | 8,206 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aquilo Capital Management, LLC | 908,474 | $24,410,696 | 22.12% |
| Western Financial Corp/CA | 820,239 | $22,039,822 | 16.16% |
| JOHNSON & JOHNSON | 247,598 | $6,652,958 | 2.45% |
| WEALTH EFFECTS LLC | 164,750 | $4,426,835 | 2.19% |
| M28 Capital Management LP | 67,400 | $1,811,038 | 2.08% |
| Privium Fund Management B.V. | 259,036 | $6,960,298 | 2.07% |
| Evolutionary Tree Capital Management, LLC | 51,266 | $1,377,517 | 1.78% |
| Avidity Partners Management LP | 1,063,897 | $28,586,912 | 1.15% |
| SECTORAL ASSET MANAGEMENT INC | 157,552 | $4,233,422 | 0.82% |
| Vivo Capital, LLC | 137,411 | $3,692,234 | 0.40% |